FindTrial
Sign In

INTRATUMOR HORMONE RECEPTOR HETEROGENEITY IN BREAST CANCER.

ASSESSMENT OF HORMONE RECEPTOR EXPRESSION HETEROGENEITY IN CARCINOMA BREAST:AN IMMUNOHISTOCHEMICAL STUDY

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/11/021957
Enrollment
60
Registered
2019-11-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C50- Malignant neoplasm of breast

Interventions

None listed

Sponsors

PRIYANKA YADAV
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Newly diagnosed cases of breast carcinoma. 2 Age more than 18 year. 3 Willing to get treated in the same hospital

Exclusion criteria

Exclusion criteria: 1 Previous endocrine or chemotherapy 2 Patients undergone lumpectomy as diagnostic procedure

Design outcomes

Primary

MeasureTime frame
IMMUNOHISTOCHEMICAL VARIATION IN ER PR HER2NEUTimepoint: 6 MONTHS—

Secondary

MeasureTime frame
ASSOCIATION OF HORMONE RECEPTOR EXPRESSION WITH REPONSE TO CHEMOTERAPYTimepoint: 6 MONTHS—

Countries

India

Contacts

Public ContactPRIYANKA YADAV

MAULANA AZAD MEDICAL COLLEGE NEW DELHI

nitakhurana@rediffmail.com9968604289

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026